/
All references in this report to "Coya," the "Company," "we," "us," or "our" mean Coya Therapeutics, Inc. unless stated otherwise or the context otherwise indicates. Overview We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells ( Tregs ).
The business is unprofitable at the operating level (-283.87% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 123.6% YoY with margins expanding 201.5pp.
ROIC dropped from -36.24% to -43.14%, capital efficiency is deteriorating.
Profitability & Returns
Revenue (TTM)
$8M
▲ +123.6% YoY
Net Income (TTM)
-$21M
▼ -42.6% YoY
Op. Margin
-283.64%
▲ +201.5pp YoY
ROIC
-48.21%
▼ -6.9pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$14M
▼ -4.4% YoY
Net Debt
-$51M
Net Cash Position
Cash & Equiv.
$51M
Continue Research